IMMA Health raises $2.5M to bring at-home ultrasound to IVF patients

Israeli medtech company IMMA Health, which develops portable ultrasound devices for women undergoing fertility treatments, announced a follow-on funding of $2.5 million as part of a $4.8 million Seed round. The investment was led by European investment group iXcore and is also supported by a grant from the Israel Innovation Authority. So far, the company has raised nearly half of the target amount, and the round remains open for additional investors.

IMMA Health aims to solve one of the main challenges in in vitro fertilization (IVF) treatments: the need for frequent and invasive clinic visits for ultrasound examinations. The company’s platform combines an autonomous robotic scanner for home use with an artificial intelligence engine that performs a 3D scan of the pelvis and automatically identifies follicles and uterine lining. The information is securely transmitted to the patient’s medical team, providing a comprehensive view of the patient’s condition.

According to CEO Beatrice Chemla, “The current fertility monitoring model is a significant barrier that limits clinic growth and negatively impacts the patient experience. For the first time, we are freeing women from this model and enabling continuous and consistent collection of clinical data from home.”

The global fertility monitoring market targeted by IMMA Health was estimated at approximately $24 billion in 2023 and is expected to double by 2030. Hervé Arditty, founder and president of iXcore, said, “IMMA Health’s technology is unique because it puts the power of ultrasound in the hands of patients without compromising the quality and accuracy that doctors demand.”

The company was founded in 2021 by Beatrice Chemla (CEO) and Dr. Nadia Prisant (CMO). The funding will be used to complete product development, expand clinical trials, and prepare for market entry in Europe and North America.